Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
42.25
+1.44 (3.54%)
Dec 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 41.11 - 43.58
52 week 31.38 - 98.00
Open 41.29
Vol / Avg. 1.40M/1.73M
Mkt cap 3.80B
P/E     -
Div/yield     -
EPS -4.54
Shares 85.81M
Beta 2.90
Inst. own 92%
Feb 9, 2017
Q4 2016 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 16, 2016
Alnylam Pharmaceuticals Inc R&D Day - 8:00AM EST - Add to calendar
Dec 4, 2016
Alnylam Pharmaceuticals to Discuss Clinical Results at ASH
Nov 30, 2016
Alnylam Pharmaceuticals Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 17, 2016
Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference - Webcast
Nov 16, 2016
Alnylam Pharmaceuticals Inc at Stifel Healthcare Conference - Webcast
Nov 15, 2016
The Medicines Company AHA Analyst Event - Webcast
Nov 7, 2016
Alnylam Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Webcast
Nov 2, 2016
Q3 2016 Alnylam Pharmaceuticals Inc Earnings Call
Nov 2, 2016
Q3 2016 Alnylam Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -762.37% -705.83%
Operating margin -781.45% -720.27%
EBITD margin - -673.91%
Return on average assets -30.98% -23.52%
Return on average equity -39.50% -26.36%
Employees 369 -
CDP Score - -

Address

300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases. Its Genetic medicines include Patisiran (ALN-TTR02) and Fitusiran (ALN-AT3), and additional genetic programs, including ALN-AAT.

Officers and directors

Michael W. Bonney Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barry E. Greene President
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
David-Alexandre Gros M.D. Principal Financial Officer, Chief Business Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
Yvonne Greenstreet Chief Operating Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D. Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
.. Bartlett Keating Senior Vice President - General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Michael P. Mason Principal Accounting Officer, Vice President, Treasurer
Age: 41
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 62
Bio & Compensation  - Reuters